| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | JAK1; JAK1A; JAK1B; Tyrosine-protein kinase JAK1; Janus kinase 1; JAK-1 |
| Entrez GeneID | 3716 |
| clone | 9A8 |
| WB Predicted band size | Calculated MW: 133 kDa; Observed MW: 130 kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Purified recombinant human Jak1 protein fragments expressed in E.coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于JAK1抗体的3篇代表性文献的虚构示例(基于真实研究领域方向整理)：
---
1. **"Selective JAK1 Inhibition in Autoimmune Disease: Mechanisms and Therapeutic Potential"**
*Smith, A. et al. (2021). Nature Reviews Immunology.*
摘要：该综述系统总结了JAK1在自身免疫疾病(如类风湿关节炎、银屑病)中的信号通路作用，探讨了特异性JAK1抗体及小分子抑制剂(如Filgotinib)的临床前和临床试验数据，强调其相比泛JAK抑制剂的低毒性优势。
2. **"Structural Basis of JAK1 Activation by Cytokine Receptors"**
*Zhang, Y. et al. (2019). Cell.*
摘要：通过冷冻电镜解析JAK1与IL-6受体复合物的结构，揭示了JAK1在受体结合后的构象变化机制，为设计靶向JAK1的功能性抗体或变构抑制剂提供了关键结构生物学依据。
3. **"JAK1 Antibody Attenuates Intestinal Inflammation in a Murine Colitis Model"**
*Tanaka, K. et al. (2020). Gastroenterology.*
摘要：研究开发了一种靶向JAK1的单克隆抗体，并在小鼠结肠炎模型中验证其通过抑制STAT3磷酸化减少肠道Th17细胞浸润和炎症反应的效果，提示其在炎症性肠病治疗中的潜力。
---
**备注**：以上文献为示例性质，实际研究中建议通过PubMed或Google Scholar检索真实文献(关键词：JAK1 antibody, JAK1 inhibitor, JAK-STAT pathway)。真实经典文献可能涉及JAK1基因敲除模型研究或已上市JAK抑制剂(如tofacitinib)的作用机制。
JAK1 (Janus kinase 1) is a member of the Janus kinase family of non-receptor tyrosine kinases, which play pivotal roles in cytokine-mediated signaling through the JAK-STAT pathway. It associates with type I and II cytokine receptors, such as interferon and interleukin receptors, and is activated upon ligand binding, leading to phosphorylation of STAT proteins that regulate gene expression. Dysregulation of JAK1 is implicated in autoimmune disorders (e.g., rheumatoid arthritis, psoriasis), inflammatory diseases, and cancers, making it a key therapeutic target.
JAK1-specific antibodies are critical tools for studying its expression, activation, and interaction networks in both physiological and pathological contexts. These antibodies enable detection of JAK1 phosphorylation states (e.g., Tyr1034/1035) or total protein levels via techniques like Western blotting, immunohistochemistry, or flow cytometry. In therapeutics, JAK1 inhibitors (e.g., tofacitinib, upadacitinib) are small molecules targeting its ATP-binding domain to suppress hyperactive signaling. While most clinical agents are kinase inhibitors, monoclonal antibodies against JAK1 itself remain less common but are explored for precision targeting in diseases with defined JAK1 mutations or overexpression.
Research also focuses on JAK1's role in immune checkpoint regulation and resistance to targeted therapies. Challenges include minimizing off-target effects against other JAK isoforms (JAK2. JAK3. TYK2). Overall, JAK1 antibodies continue to advance mechanistic studies and therapeutic development in immunology and oncology.
(Word count: 199)
×
